Autoimmune Hepatitis Pipeline Analysis report covers drugs of 7 companies currently in different phases of development. Autoimmune hepatitis is a long-lasting disease in which the body’s immune system fights against the normal liver cells instead of fighting against bacteria, viruses or other foreign substances. This gives rise to the liver inflammation leading to liver damage and failure. If diagnosed early, autoimmune hepatitis can be treated via immunosuppressive drugs. The exact cause of the disease is however unknown. There are two types of autoimmune hepatitis identified as type 1 autoimmune hepatitis, most common type of disease which can occur at any age, and type 2 autoimmune hepatitis which is most common in children and young people. However, it can occur in adults too.
The report provides Autoimmune Hepatitis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Novartis AG, ILTOO Pharma and Revive Therapeutics Ltd. among others.
By Molecule Type
By Route of Administration